Mylan Gets 2030 Linzess Launch After Allergan Deal
Mylan Pharmaceuticals Inc. will hold off on its generic version of Allergan PLC and Ironwood Pharmaceuticals Inc.'s irritable bowel syndrome medication Linzess until February 2030 to end patent infringement litigation in...To view the full article, register now.
Already a subscriber? Click here to view full article